Skip to content
Study details
Enrolling now

Evaluation of 18F-Fluciclovine PET-MRI in LGG

Children's Hospital of Philadelphia
NCT IDNCT05555550ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

30

Study length

about 1.8 years

Ages

1–21

Locations

1 site in PA

What this study is about

This trial is testing if 18F-Fluciclovine (Axumin®) is useful and safe for children with Low Grade Gliomas (LGG). Imaging will be performed before, during, and after treatment to see how changes in 18F-Fluciclovine uptake compare to MRI measurements.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take 18F-Fluciclovine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

fluciclovine (18F)

Endpoints

Primary: Compare changes in pretreatment tumor measurement on MRI in pediatric participants who initiate systemic treatment for LGG

Body systems

Neurology